振东制药以自有资金3000万元投资生物医药基金

Group 1 - The stock price of Zhendong Pharmaceutical has shown volatility in the past week, closing at 6.16 yuan on February 27, 2026, with a daily increase of 0.65% and a cumulative increase of 0.49% over the last five days [1] - On February 26, 2026, the stock price experienced a notable decline of 1.77%, with a net outflow of 16.08 million yuan from major funds and a turnover rate of 2.54% [1] - Technical analysis indicates that the current stock price is near the middle track of the 20-day Bollinger Bands, with a resistance level at 6.55 yuan and a support level at 5.55 yuan [1] Group 2 - On February 24, 2026, Zhendong Pharmaceutical announced the resignation of its president Yang Lianmin due to retirement, with Lei Zhenhong elected as the employee representative director [2] - The company also announced an investment of 30 million yuan from its own funds to participate in a biopharmaceutical fund, holding a 28.57% stake [2] - The 2024 annual board work report mentioned the completion of efficacy evaluation for a new skin drug in the innovative drug sector and progress on the FDA registration of a compound injection [2] Group 3 - The Q3 2025 financial report indicated that Zhendong Pharmaceutical's revenue for the first three quarters was 2.215 billion yuan, a year-on-year decrease of 2.42%, while the net profit attributable to shareholders was 20.3641 million yuan, down 49.25% year-on-year [3] - In Q3 alone, the revenue was 758 million yuan, with a net profit of 12.4328 million yuan, reflecting a year-on-year increase of 31.34%, and a turnaround in non-recurring net profit [3] - The decline in performance was primarily attributed to reduced investment income and increased income tax expenses [3] Group 4 - Institutional research indicates that the market attention towards Zhendong Pharmaceutical is average, with the latest sentiment being neutral; 0% of institutional ratings are positive, 0% are negative, and 100% are neutral [4] - Earnings forecasts suggest that the earnings per share for 2024 will be negative, and the proportion of fund holdings is relatively low [4]